Zepbound treatment involves several potential risks that should be discussed before starting medication. Some reactions are temporary, while others may require medical assessment or treatment discontinuation.
Gastrointestinal problems: Nausea, vomiting, diarrhoea, constipation, and abdominal pain are commonly reported. Severe digestive symptoms may require medical attention.
Pancreatitis: Inflammation of the pancreas is a potential serious complication. Persistent or severe abdominal pain, particularly when spreading towards the back, requires immediate medical evaluation.
Gallbladder problems: Gallstones and gallbladder inflammation have been reported. Symptoms may include upper abdominal pain, fever, and yellowing of the skin or eyes.
Kidney complications: Persistent vomiting or diarrhoea can cause dehydration, potentially affecting kidney function.
Thyroid tumour warning: Studies in rats identified thyroid C-cell tumours. Whether this risk applies to humans remains unknown. Zepbound should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Allergic reactions: Serious hypersensitivity reactions, including swelling and difficulty breathing, have been reported.
Low blood glucose: Hypoglycemia may occur, particularly when Zepbound is combined with insulin or certain diabetes medications.
Patients experiencing severe abdominal pain, breathing difficulties, significant dehydration, or symptoms of a serious allergic reaction require prompt medical attention.
Medical monitoring helps healthcare professionals assess treatment response, identify complications, and determine whether the medication remains appropriate. Monitoring requirements depend on individual health conditions, other medications, and treatment progress.
Weight assessment: Healthcare professionals may regularly evaluate body weight and changes in weight management outcomes.
Blood glucose monitoring: Patients with diabetes may require glucose assessments, particularly when using insulin or other glucose-lowering medications.
Kidney function: Kidney function should be assessed when persistent vomiting, diarrhoea, or dehydration occurs.
Digestive health: Healthcare professionals should evaluate severe or persistent gastrointestinal symptoms and consider whether further investigation is necessary.
Gallbladder assessment: Symptoms suggesting gallbladder disease may require imaging investigations and clinical evaluation.
Medication review: Other prescription medications should be reviewed because Zepbound delays stomach emptying and may affect the absorption of oral medicines.
Pregnancy considerations: Zepbound may cause fetal harm. Treatment should be discontinued when pregnancy is recognized. Patients using oral contraceptives should discuss additional or alternative contraception during treatment initiation and dosage increases.
Surgical procedures: Patients should inform healthcare professionals about Zepbound use before undergoing surgery or procedures involving general anesthesia or deep sedation because delayed stomach emptying may increase aspiration concerns.
Patients should also disclose their medical history, existing digestive conditions, allergies, and current medications before beginning treatment. Regular consultations allow healthcare professionals to evaluate adverse reactions and provide appropriate guidance throughout treatment.
Zepbound treatment requires an individualized approach based on medical history, treatment response, and potential adverse reactions. Appropriate clinical supervision and timely reporting of unusual symptoms support safer medication use and help healthcare professionals make informed decisions about ongoing treatment.